Literature DB >> 25559230

Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.

Yoon Jin Lee1, Jeong Min Lee, Ji Sung Lee, Hwa Young Lee, Bo Hyun Park, Young Hoon Kim, Joon Koo Han, Byung Ihn Choi.   

Abstract

PURPOSE: To perform a systematic review and meta-analysis of the diagnostic performance of computed tomography (CT) and magnetic resonance (MR) imaging as noninvasive modalities for evaluating hepatocellular carcinoma (HCC) in patients with chronic liver disease.
MATERIALS AND METHODS: A search of the MEDLINE, EMBASE, and Cochrane Library databases was performed to identify studies providing per-patient or per-lesion diagnostic accuracies of multidetector CT and MR imaging for HCCs in patients with chronic liver disease. Studies published from January 2000 to December 2012 that used a reference standard based on histopathologic findings and/or findings at follow-up were included. Summary estimates of diagnostic accuracy were obtained by using a random-effects model with further exploration with meta-regression and subgroup analyses.
RESULTS: Forty studies (six on multidetector CT, 22 on MR imaging, and 12 on both CT and MR imaging) were included. The studies evaluated a total of 1135 patients with multidetector CT and 2489 patients with MR imaging. The overall per-patient sensitivity of MR imaging was 88% (95% confidence interval [CI]: 83%, 92%), with a specificity of 94% (95% CI: 85%, 98%). The overall per-lesion sensitivity of MR imaging was higher than that of multidetector CT when the paired data of the 11 available studies were pooled (80% vs 68%, P = .0023). Gadoxetic acid-enhanced MR imaging showed significantly higher per-lesion sensitivity than MR imaging performed with other contrast agents (87% vs 74%, P = .03). Per-lesion sensitivity was significantly lower for HCCs smaller than 1 cm than that for HCCs 1 cm or larger (P < .001 for CT, P = .02 for MR imaging) and for those in explanted livers (P = .04 for CT, P < .001 for MR imaging).
CONCLUSION: MR imaging showed higher per-lesion sensitivity than multidetector CT and should be the preferred imaging modality for the diagnosis of HCCs in patients with chronic liver disease. © RSNA, 2015 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25559230     DOI: 10.1148/radiol.14140690

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  126 in total

Review 1.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

2.  A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression.

Authors:  Zhenzhen Liu; Mei-Juan Tu; Chao Zhang; Joseph L Jilek; Qian-Yu Zhang; Ai-Ming Yu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-06-02       Impact factor: 3.205

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  [CT and MRI of the liver: when, what, why?]

Authors:  J Budjan; S O Schoenberg; U I Attenberger
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

5.  Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

Review 6.  Updates on Imaging of Liver Tumors.

Authors:  Arya Haj-Mirzaian; Ana Kadivar; Ihab R Kamel; Atif Zaheer
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

7.  Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.

Authors:  Dong Ho Lee; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

8.  Evaluation of Transient Motion During Gadoxetic Acid-Enhanced Multiphasic Liver Magnetic Resonance Imaging Using Free-Breathing Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Kai Tobias Block; Hersh Chandarana; Berthold Kiefer; Yohan Son
Journal:  Invest Radiol       Date:  2018-01       Impact factor: 6.016

Review 9.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

10.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.